Tempest Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
07 janv. 2021 08h00 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and...
Sam Whiting, M.D., Ph.D., Joins Tempest as Executive Vice President and Chief Medical Officer
21 oct. 2020 08h00 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and...
Tempest Therapeutics to Present at Two Investor Conferences in August
31 juil. 2020 08h00 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and...
Tempest Therapeutics Announces First Patient Dosed With the Combination of TPST-1120 Plus Nivolumab in a Phase 1 Study in Patients With Advanced Solid Tumors
22 juin 2020 08h00 HE
|
Tempest Therapeutics
Combination regimen will treat patients with cholangiocarcinoma, liver and kidney cancersFirst step in broader combination strategy given TPST-1120’s novel mechanism of action SOUTH SAN FRANCISCO,...
Tempest Therapeutics Announces First Patient Dosed in TPST-1495 Clinical Study: Dual EP2/4 Antagonist Targeting Solid Tumors
07 mai 2020 08h30 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and...
Tempest Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference
24 févr. 2020 16h00 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage oncology company developing therapeutics that combine both precision and immune-mediated...
Tempest Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPST-1495 and Welcomes New Investors
30 janv. 2020 08h00 HE
|
Tempest Therapeutics
TPST-1495 is a selective dual antagonist of both EP2 and EP4 prostaglandin receptorsLyfe Capital and Rock Springs Capital Management join investor syndicate SOUTH SAN FRANCISCO, Calif., Jan. 30,...
Tempest Therapeutics’ Oncology Programs Presented at Society of Immunotherapy for Cancer Annual Meeting
08 nov. 2019 08h00 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing a broad portfolio of first-in-class small molecule...
Tempest Therapeutics Names Biopharmaceutical Executive Stephen Brady as President and Chief Operating Officer
07 oct. 2019 08h00 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing a diverse portfolio of first-in-class small molecules...
Tempest Therapeutics Announces Multiple Presentations at Upcoming SITC 34th Annual Meeting
02 oct. 2019 16h00 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing a broad portfolio of first-in-class small molecules...